Comparison of patients' characteristics at diagnosis
| Characteristic . | Patients with ACAs (N = 21) . | Patients without ACAs (N = 357) . | P . |
|---|---|---|---|
| Median age, y (range) | 45 (24-74) | 50 (18-84) | .18 |
| Sex, male/female, N (%) | 18/3 (86/14) | 210/147 (59/41) | .02 |
| Median spleen, cm (range) | 4 (0-21) | 2 (0-23) | .10 |
| Median Hb level, g/dL (range) | 11.8 (8.2-16.0) | 12.0 (6.4-17.5) | .77 |
| Median PLT count, 109/L (range) | 406 (143-979) | 346 (107-4920) | .79 |
| Median peripheral blasts, % (range) | 2.5 (1-8) | 1 (0-10) | .03 |
| Median eosinophils, % (range) | 3 (0-6) | 2 (0-15) | .53 |
| Medin basophils, % (range) | 2 (0-10) | 2 (0-19) | .82 |
| Sokal score, N (%) | .66 | ||
| Low | 7 (33) | 140 (39) | |
| Intermediate | 6 (29) | 134 (38) | |
| High | 8 (38) | 83 (23) | |
| Hasford score, N (%) | .35 | ||
| Low | 6 (29) | 159 (45) | |
| Intermediate | 13 (62) | 173 (48) | |
| High | 2 (10) | 25 (7) | |
| EUTOS score, N (%) | .20 | ||
| Low | 18 (86) | 338 (95) | |
| High | 3 (14) | 19 (5) | |
| Variant Ph translocations, N (%) | 1 (5) | 24 (7) | 1.00 |
| Deletions der(9), N (%) | 4 (19) | 36 (10) | .26 |
| Imatinib dose (mg), N (%) | .81 | ||
| 400 | 16 (76) | 258 (72) | |
| 800 | 5 (24) | 99 (28) |
| Characteristic . | Patients with ACAs (N = 21) . | Patients without ACAs (N = 357) . | P . |
|---|---|---|---|
| Median age, y (range) | 45 (24-74) | 50 (18-84) | .18 |
| Sex, male/female, N (%) | 18/3 (86/14) | 210/147 (59/41) | .02 |
| Median spleen, cm (range) | 4 (0-21) | 2 (0-23) | .10 |
| Median Hb level, g/dL (range) | 11.8 (8.2-16.0) | 12.0 (6.4-17.5) | .77 |
| Median PLT count, 109/L (range) | 406 (143-979) | 346 (107-4920) | .79 |
| Median peripheral blasts, % (range) | 2.5 (1-8) | 1 (0-10) | .03 |
| Median eosinophils, % (range) | 3 (0-6) | 2 (0-15) | .53 |
| Medin basophils, % (range) | 2 (0-10) | 2 (0-19) | .82 |
| Sokal score, N (%) | .66 | ||
| Low | 7 (33) | 140 (39) | |
| Intermediate | 6 (29) | 134 (38) | |
| High | 8 (38) | 83 (23) | |
| Hasford score, N (%) | .35 | ||
| Low | 6 (29) | 159 (45) | |
| Intermediate | 13 (62) | 173 (48) | |
| High | 2 (10) | 25 (7) | |
| EUTOS score, N (%) | .20 | ||
| Low | 18 (86) | 338 (95) | |
| High | 3 (14) | 19 (5) | |
| Variant Ph translocations, N (%) | 1 (5) | 24 (7) | 1.00 |
| Deletions der(9), N (%) | 4 (19) | 36 (10) | .26 |
| Imatinib dose (mg), N (%) | .81 | ||
| 400 | 16 (76) | 258 (72) | |
| 800 | 5 (24) | 99 (28) |
Hb indicates hemoglobin; PLTs, platelets; and EUTOS, European Treatment and Outcome Study.